GLOBALMalwareHealthcareHealthcareRansomwareMorpheusRansom DemandedActor NamedMedium
Alora Pharmaceuticals, LLC
bd_3d695a4b3ba42581 · schema v1 · pii pii-v1
Full breach record for Alora Pharmaceuticals, LLC →Threat-actor claim — not a regulatory filing
This row is a claim by the ransomware group Morpheus on its public extortion blog. It has not been validated by the victim or any regulator. Treat attribution and counts as the threat actor's assertion until a regulatory filing or victim disclosure corroborates them.
Group activity: HealthcareDiscovered: 2025-04-01
Source: Ransomware.live
Post text · scraped from the leak site
**Website**: alorapharma.com acellapharma.com avionrx.com osmotica.com sovpharm.com trigenlab.com verticalpharma.com **Revenue**: $337.4 Million Alora Pharmaceuticals, LLC is a parent company of si
Tracked as a single-filing incident — the only disclosure on record for this event so far.Unverified claimView incident
No regulatory filing corroborates this yet. If an SEC 8-K, state-AG notice, or victim statement lands, DisclosureLens will merge it into an incident and link it here.
Source provenance
- Source URL
- https://www.ransomware.live/
DisclosureLens links to the originating regulator URL — full filing bodies are not redistributed from public surfaces (§4.5).
- Filed at
- Apr 1, 2025
- Raw hash
- 694c6fa62b8c495b9d400b31dd24ba7b69ad1b617695aefa63ae062bb54d35a7
Reporting entity
- Name
- morpheus
Victim entity
- Name
- Alora Pharmaceuticals, LLCnorm: alora pharmaceuticals
- Domain
- alorapharma.com
- Industry
- Healthcarellm
What this source establishes
- Source ceiling
- A leak-site claim can't tell us: discovery date · materiality · notification · affected count · confirmed data types · compliance clock. These stay blank until a regulatory filing or victim disclosure lands.
- Attack vector
- Ransomware· morpheus
- Threat actor
- MorpheusExternalFinancial
Compliance
- Compliance flags
- — (clock not assessable for this source)
Extraction provenance
- Status
- No extraction artifact recorded for this disclosure.